消息面,百济神州2025年4月30日公告称,美国专利商标局(USPTO)作出了一项最终书面决定,宣布Pharmacyclics LLC在专利授权后复审(PGR)程序中受到公司质疑的第11,672,803号美国专利的全部权利无效。受利好刺激,创新药板块盘初拉升,相关ETF——创新药沪深港ETF涨超1%,年初至今涨近14%。相关机构表示,百济神州获胜意味着中国创新药国际化之路取得了阶段性胜利,这也是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.